
    
      This study will evaluate the safety, tolerability, pharmacokinetics, metabolites,
      pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors
      with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS
      G12C.
    
  